MariaBusiness Director

The organisation was wonderful, the presentations were really enlightening, from very important people of the field. This event is highly recommended and will definitely come next year as well!

EleniCMC/Safety toxicologist, EUROTOX Member

🌟 What a great experience attending the "9th Impurities: Genotoxic, Nitrosamine & Beyond" summit in Vienna earlier this April! 🌟 The event featured exceptional speakers and an inspiring scientific community. I left with valuable insights and key takeaways that will undoubtedly impact my work.

SaraPreclinical Development Manager

It’s been almost a week since the conclusion of the inspiring 9th Impurities #Egenotoxic congress. I’m truly grateful for the opportunity to learn from outstanding professionals and to further strengthen connections with amazing colleagues. Quality and safety always go hand in hand, supporting each other to prevent risks and ensure the most technologically and scientifically safe product for human health.

ChristinaAnalytical Chemist

I had the incredible opportunity to participate in the 9th Impurities: Genotoxic, Nitrosamine & Beyond Summit I hashtag#Egenotoxic in Vienna. This two-day journey was a deep dive into the complex but fascinating world of nitrosamines. Exceptional scientists shared generously their expertise across a wide range of topics, from toxicological concerns and regulatory inconsistencies to analytical challenges... ... 👩‍🔬 I returned with valuable takeaways, new connections, and a renewed passion for continuing to learn and contribute to this vital and evolving area of research.

KevenToxicologist & Risk Assessor | Expert in Nitrosamines, Impurities & Exposure Limits | Supporting Global Pharma Compliance & Product Safety

Wrapping up an inspiring conference at the #Egenotoxic in Vienna. One key challenge echoed through many sessions: navigating a fragmented regulatory landscape. In particular, the ongoing inconsistencies around the acceptance of durational-based limits, whether for nitrosamines or non-mutagenic impurities, and the required supportive in vitro/in vivo genotoxicity testing continue to create a lot of uncertainty. As Dr. Lutz Mueller reminded us, carcinogenic risk is never as simple as a single number. Beyond mechanistic or epigenetic factors, it’s shaped by study design, biological variability, and interspecies differences. Over-simplifying that complexity can lead to over-conservatism, which also carries consequences for patients. On a more positive note, it was encouraging to hear that NDSRI test results so far suggest much lower potency than small dialkyl nitrosamines, hopefully paving the way for more pragmatic, science-based approaches. Stay tuned for some very promising work from Johnson et al. A special highlight for me was meeting David Ponting from Lhasa Limited, whose work I’ve long admired, and even managing to capture the moment! Grateful for the openness and generosity of everyone I connected with, and energized to keep learning, exchanging, and contributing to this fast-moving field.

SophiaToxicology Lead

I appreciate the comprehensive approach #Egenotoxic takes — covering everything from cutting-edge analytical techniques to regulatory updates. It’s the perfect platform to stay ahead of industry challenges and network with top experts.